充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
Association of Cardiovascular Disease With Respiratory Disease
The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
AIM2-driven inflammasome activation in heart failure
A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics.
The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment
Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

|<<... 10 11 12 13 14 15 16 >>|

Review Article

2017 Nov;5(11):763-771.

JOURNAL：JACC Heart Fail.

Article Link

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

Hsu JJ, Ziaeian B, Fonarow GC.

4612

Keywords: HFbEF; HFmrEF; HFpEF; epidemiology; heart failure with borderline ejection fraction; heart failure with mid-range ejection fraction; heart failure with preserved ejection fraction; outcomes

FULL TEXT PDF